Physician profile
James D Pollard
NPI 1174786651
$951.70
in general payments reported to CMS, 2019-2025
12 companies · $22.85 in 2025
The $22.85 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $89.22 · 2021: $137 · 2022: $61.13 · 2023: $25.90 · 2024: $138 · 2025: $22.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $217.63 | 2019-2023 | |
| Pfizer INC. | $216.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.32 | 2019 | |
| Heartflow, INC. | $120.77 | 2024 | |
| Btg International INC. | $100.80 | 2019 | |
| Gilead Sciences, INC. | $77.28 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.33 | 2020 | |
| Irhythm Technologies, INC. | $17.15 | 2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $14.32 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Astellas Pharma US INC | $13.40 | 2019 | |
| Ge Healthcare | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.